30 Background: Depression affects approximately 25% of people with MS (pwMS) at any given time. It is 31 however under recognised in clinical practice, in part due to a lack of uptake for brief assessment tools 32 and uncertainty about their psychometric properties. The 9-item Patient Health Questionnaire (PHQ-9) is 33 an attractive candidate for this role. 34 35 Objective: To synthesise published findings on the psychometric properties of the 9-item Patient Health 36 Questionnaire (PHQ-9) when applied to people with multiple sclerosis (pwMS). 37 38 Data sources: PubMed, Medline and ISI Web of Science databases, supplemented by hand-searching of 39 references from all eligible sources. 40 41 Study eligibility criteria: Primary literature written in English and published following peer-review with 42 a primary aim to evaluate the performance of the PHQ-9 in pwMS. 43 44 Outcome measures: Psychometric performance with respect to appropriateness, reliability, validity, 45 responsiveness, precision, interpretability, acceptability, and feasibility. 46 47 Results: Seven relevant studies were identified, these were of high quality and included 5080 participants 48 from all MS disease-course groups. Strong evidence was found supporting the validity of the PHQ-9 as a Publications Ltd; 2006 Apr;12(2):204-8.
49 unidimensional measure of depression. Used as a screening tool for major depressive disorder (MDD) 50 with a cut-point of 11, sensitivity was 95% sensitivity and specificity 88.3% (PPV 51.4%, NPV 48.6%).
51 Alternative scoring systems that may address the issue of overlap between somatic features of depression 52 and features of MS per se are being developed, although their utility remains unclear. However data on 53 reliability was limited, and no specific evidence was available on test-retest reliability, responsiveness, 54 acceptability, or feasibility.
56 Conclusions: The PHQ-9 represents a suitable tool to screen for MDD in pwMS. However use as a 57 diagnostic tool cannot currently be recommended, and the potential value for monitoring depressive 58 symptoms cannot be established without further evidence on test-retest reliability, responsiveness, 59 acceptability, and feasibility. 80 Multiple sclerosis (MS) is estimated to affect over 2.3 M people globally(1). It is a chronic inflammatory 81 and degenerative disease of the central nervous system that typically results in sensory, motor, and 82 cognitive impairments(2). The potential co-existence of depression in people with MS (pwMS) is well 83 recognised, with a lifetime prevalence >50%, point prevalence of approximately 25%(3), and doubling of 84 the standardized mortality rate for suicide compared to the general population(4). Depression in pwMS is 85 nevertheless underdiagnosed in clinical practice(5) despite being a major determinant of quality of life(6), 86 and responsive to standard therapeutic approaches(7). This in part may reflect uncertainty around the 87 optimum approach to evaluation. A 'gold-standard' approach based on the Structured Clinical Interview 96 is notable in this context because it is freely available and has been validated across a wide range of 97 clinical populations(9). The PHQ-9 is a self-report version of the Primary Care Evaluation of Mental 98 Disorders (PRIME-MD), developed in the mid-1990s by Pfizer Inc.(10) It evaluates depressive symptoms 99 over the preceding two weeks, with 9-items each allowing four response-options for the frequency of 100 symptom-experience. A total score is derived by summation, and interpreted against established 101 thresholds. Despite the potential advantages of the PHQ-9 as a tool to evaluate depressive symptoms in 102 pwMS, there have been no previous focused reviews of the PHQ-9's psychometric performance in this 185 raised the possibility that a number of participants (up to 12%) had been analysed twice (Table 2) . 
291
292 Kim et al.(17) investigated the potential for PHQ-9 scores to be interpreted with respect to their 293 equivalent PROMIS-D depression scores, estimating these through a process termed 'cross-walking'. The 294 correlation between the direct PROMIS-D score and the 'cross-walked' PHQ-9 was moderately strong at 295 0.74. 56.6% of patients were categorized into the same PHQ-9 severity categories based both on actual 296 and cross-walked scores, with 9.2% put into one lower category, 1.7% put in more than one category 297 lower, 27.7% put one category higher and 4.8% classified into more than one category higher. Overall it 298 was found that the PHQ-9 was most suitable for conversion to 'cross-walked' PROMIS-D scores in those 299 with average to high depressive symptoms. 300 301 Acceptability 302 No study explicitly investigated the acceptability of completing the PHQ-9 to pwMS. However, no 303 substantial concerns were raised in prospectively recruiting studies where recruitment rate ranged from 304 28.8% to 98.1%, and retention/completion rate in longitudinal research was 80.9%.
306 Feasibility
307 None of the studies explicitly investigated the feasibility of administering the PHQ-9 to pwMS. However, 308 the literature includes a mixture of participants drawn from both primary and secondary care settings.
